Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives.
dagger]) The EGAPP Working Group was established in 2005 to support the development of a systematic process for assessing the available evidence regarding the validity and utility of rapidly emerging genetic tests for clinical practice.
In the 2007 report, EGAPP examined the usefulness of genetic testing for cytochrome P450 (CYP450) before prescribing SSRI antidepressants.
The biggest problem facing EGAPP is the genetic testing deluge.
Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors.
Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?
Working Group releases the first in a planned series of recommendation statements on the use of genetic tests in clinical practice.
In December, EGAPP
published a report on genomic profiling to assess cardiovascular risk (Genet.
Testing for Lynch syndrome is frequently covered by payers, based on the positive evidence review conducted by EGAPP
(Evaluation of Genomic Applications in Practice and Prevention).
Teutsch is a member of the EGAPP
(Evaluation of Genomic Applications in Practice and Prevention) working group, an independent body organized in 2004 by the Centers for Disease Control and Prevention to provide guidance on the appropriate use of genetic tests in clinical practice.
is an independent body supported by the Centers for Disease Control and Prevention.
Teutsch SM, Bradley LA, Palomaki GE, et al: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP
) initiative: Methods of the EGAPP